The bio-corona and its impact on nanomaterial toxicity

European Journal of Nanomedicine

Volumn 7, Issue 3, 2015, Pages 153-168

  Westmeier, Dana ^a   Chen, Chunying ^b   Stauber, Roland H ^a   Docter, Dominic ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

bioinformatics; blood system; label free quantification; mass spectrometry; nanomedicine; nanoparticles; nanotoxicology; proteomics; systems biology

Indexed keywords

BIOINFORMATICS; MASS SPECTROMETRY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; NANOSTRUCTURED MATERIALS; PROTEOMICS; TOXICITY;

BLOOD SYSTEM; FORMATION AND EVOLUTIONS; LABEL FREE; MOLECULAR BUILDING BLOCKS; NANOTOXICOLOGY; NATURAL ENVIRONMENTS; SYSTEMS BIOLOGY; TOXICITY MECHANISMS;

BLOOD;

BIOCORONA NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

ENZYME INHIBITION; EVOLUTION; HUMAN; MOLECULAR SIZE; NANOTOXICOLOGY; PREVENTION; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; PROTEOMICS; REVIEW; STRUCTURE ACTIVITY RELATION; SYSTEMS BIOLOGY;

EID: 84931066206     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2015-0018     Document Type: Review

References (136)

1. Reese M. Nanotechnology: using co-regulation to bring regulation of modern technologies into the 21st century. Health Matrix 2013;23:537-72.
2. Webster TJ. Interview: Nanomedicine: past, present and future. Nanomed: Nanotechnol, Biol Med 2013;8:525-9.
3. Docter D, Strieth S, Westmeier D, Hayden O, Gao M, Knauer SK, et al. No king without a crown - impact of the nanomaterial-protein corona on nanobiomedicine. Nanomedicine (Lond) 2015;10:503-19.
4. Rauscher H, Sokull-Kluttgen B, Stamm H. The European Commissions recommendation on the definition of nanomaterial makes an impact. Nanotoxicology 2013;7:1195-7.
5. Pautler M, Brenner S. Nanomedicine: promises and challenges for the future of public health. Int J Nanomed 2012;5:803-9.
6. Ranganathan R, Madanmohan S, Kesavan A, Baskar G, Krishnamoorthy YR, Santosham R, et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomed 2012;7:1043-60.
7. Ventola CL. The nanomedicine revolution: part 3: regulatory and safety challenges. P & T: A Peer-Rev J Formulary Manage 2012;37:631-9.
8. Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotech 2013;24:1159-66.
9. Seeney C, Ojwang JO, Weiss RD, Klostergaard J. Magnetically vectored platforms for the targeted delivery of therapeutics to tumors: history and current status. Nanomed: Nanotechnol, Biol Med 2012;7:289-99.
10. Prabhu P, Patravale V. The upcoming field of theranostic nanomedicine: an overview. J Biomed Nanotechnol 2012;8: 859-82.
11. Murday JS, Siegel RW, Stein J, Wright JF. Translational nanomedicine: status assessment and opportunities. Nanomed: Nanotechnol, Biol Med 2009;5:251-73.
12. Ferrari M. Nanogeometry: beyond drug delivery. Nat Nanotechnol 2008;3:131-2.
13. Qian X, Peng XH, Ansari DO, Yin-Goen Q, Chen GZ, Shin DM, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol 2008;26:83-90.
14. Ventola CL. The nanomedicine revolution: part 2: current and future clinical applications. P & T: A Peer-Rev J Formulary Manage 2012;37:582-91.
15. Hou L, Zhu D, Wang X, Wang L, Zhang C, Chen W. Adsorption of phenanthrene, 2-naphthol, and 1-naphthylamine to colloidal oxidized multiwalled carbon nanotubes: effects of humic acid and surfactant modification. Environ Toxicol Chem/SETAC 2013;32:493-500.
16. Hu FQ, Wei L, Zhou Z, Ran YL, Li Z, Gao MY. Preparation of biocompatible magnetite nanocrystals for in-vivo magnetic resonance detection of cancer. Adv Mater 2006;18:2553-6.
17. Nystrom AM, Fadeel B. Safety assessment of nanomaterials: implications for nanomedicine. J Control Release: Off J Controll Release Soc 2012;161:403-8.
18. Bawa R. Regulating nanomedicine-can the FDA handle it? Curr Drug Del 2011;8:227-34.
19. Oberdorster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 2010;267:89-105.
20. Baun A, Hansen SF. Environmental challenges for nanomedicine. Nanomed: Nanotechnol, Biol Med 2008;3:605-8.
21. Rahman M, Ahmad MZ, Kazmi I, Akhter S, Afzal M, Gupta G, et al. Emergence of nanomedicine as cancer targeted magic bullets: recent development and need to address the toxicity apprehension. Curr Drug Discov Technol 2012;9:319-29.
22. Zhu M, Nie G, Meng H, Xia T, Nel A, Zhao Y. Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Accounts Chem Res 2012;46:622-31.
23. Manke A, Wang L, Rojanasakul Y. Mechanisms of nanoparticle- induced oxidative stress and toxicity. BioMed Res Int 2013;2013:942916.
24. AshaRani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 2009;3:279-90.
25. Lunov O, Syrovets T, Rocker C, Tron K, Nienhaus GU, Rasche V, et al. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 2010;31:9015-22.
26. Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V. A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit Rev Toxicol 2010;40:328-46.
27. Ju-Nam Y, Lead JR. Manufactured nanoparticles: an overview of their chemistry, interactions and potential environmental implications. Sci Tot Environm 2008;400:396-414.
28. Li N, Xia T, Nel AE. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic Biol Med 2008;44:1689-99.
29. Stone V, Johnston H, Clift MJ. Air pollution, ultrafine and nanoparticle toxicology: cellular and molecular interactions. IEEE Trans Nanobiosci 2007;6:331-40.
30. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. Angew Chem Int Ed Engl 2009;48:872-97.
31. Oberdorster G. Nanotoxicology: in vitro-in vivo dosimetry. Environ Health Persp 2012;120:A13; author reply A.
32. Li J, Chen YC, Tseng YC, Mozumdar S, Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Controll Release: Official J Controll Release Soc 2010;142:416-21.
33. Monopoli MP, Walczyk D, Campbell A, Elia G, Lynch I, Bombelli FB, et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J Am Chem Soc 2011;133:2525-34.
34. Jeong SK, Kwon MS, Lee EY, Lee HJ, Cho SY, Kim H, et al. BiomarkerDigger: a versatile disease proteome database and analysis platform for the identification of plasma cancer biomarkers. Proteomics 2009;9:3729-40.
35. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2011;56:177-85.
36. Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol 2013;8:772-81.
37. Monopoli MP, Bombelli FB, Dawson KA. Nanobiotechnology: nanoparticle coronas take shape. Nat Nanotechnol 2011;6: 11-2.
38. Nel AE, Madler L, Velegol D, Xia T, Hoek EM, Somasundaran P, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009;8:543-57.
39. Klein J. Probing the interactions of proteins and nanoparticles. Proc Natl Acad Sci USA 2007;104:2029-30.
40. Cedervall T, Lynch I, Lindman S, Berggrd T, Thulin E, Nilsson H, et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 2007;104:2050-5.
41. Treuel L, Malissek M. Interactions of nanoparticles with proteins: determination of equilibrium constants. Method Mole Biol 2013;991:225-35.
42. Lacerda SH, Park JJ, Meuse C, Pristinski D, Becker ML, Karim A, et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano 2010;4:365-79.
43. Gebauer JS, Malissek M, Simon S, Knauer SK, Maskos M, Stauber RH, et al. Impact of the nanoparticle-protein corona on colloidal stability and protein structure. Langmuir: ACS J Surface Colloids 2012;28:9673-9.
44. Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol 2012;7:779-86.
45. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 2008;105:14265-70.
46. Walkey CD, Olsen JB, Song F, Liu R, Guo H, Olsen DW, et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 2014;8:2439-55.
47. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, Dawson KA. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci 2007.
48. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell sees in bionanoscience. J Am Chem Soc 2010;132:5761-8.
49. Treuel L, Brandholt S, Maffre P, Wiegele S, Shang L, Nienhaus GU. Impact of protein modification on the protein corona on nanoparticles and nanoparticle-cell interactions. ACS Nano 2014;8:503-13.
50. Treuel L, Eslahian KA, Docter D, Lang T, Zellner R, Nienhaus K, et al. Physicochemical characterization of nanoparticles and their behavior in the biological environment. Phys Chem Chem Phys 2014;16:15053-67.
51. Toke ER, Lorincz O, Somogyi E, Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int J Pharmaceutics 2010;392:261-7.
52. Wolfram J, Yang Y, Shen J, Moten A, Chen C, Shen H, et al. The nano-plasma interface: Implications of the protein corona. Colloid surface 2014;124:17-24.
53. Leszczynski J. Bionanoscience: Nano meets bio at the interface. Nat Nanotechnol 2010;5:633-4.
54. Adiseshaiah PP, Hall JB, McNeil SE. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010;2:99-112.
55. Dobrovolskaia MA, Neun BW, Man S, Ye X, Hansen M, Patri AK, et al. Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles. Nanomed: Nanotechnol, Biol Med, 2014;10:1453-63.
56. Tenzer S, Docter D, Rosfa S, Wlodarski A, Kuharev J, Rekik A, et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 2011;5:7155-67.
57. Thomas CR, George S, Horst AM, Ji Z, Miller RJ, Peralta-Videa JR, et al. Nanomaterials in the environment: from materials to highthroughput screening to organisms. ACS Nano 2011;5:13-20.
58. Xia XR, Monteiro-Riviere NA, Riviere JE. An index for characterization of nanomaterials in biological systems. Nat Nanotechnol 2010;5:671-5.
59. Zhang H, Burnum KE, Luna ML, Petritis BO, Kim JS, Qian WJ, et al. Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size. Proteomics 2011;11:4569-77.
60. Walkey CD, Olsen JB, Guo H, Emili A, Chan WC. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc 2012;134:2139-47.
61. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev 2012;41:2780-99.
62. Hajipour MJ, Laurent S, Aghaie A, Rezaee F, Mahmoudi M. Personalized protein coronas: a key factor at the nanobiointerface. Biomater Sci 2014;2:1210-21.
63. Caracciolo G, Pozzi D, Capriotti AL, Cavaliere C, Piovesana S, Amenitsch H, et al. Lipid composition: a key factor for the rational manipulation of the liposome-protein corona by liposome design. RSC Adv 2015;5:5967-75.
64. Caracciolo G. Liposome-protein corona in a physiological environment: Challenges and opportunities for targeted delivery of nanomedicines. Nanomed: Nanotechnol, Biol Med 2015;11:543-57.
65. Chakraborty S, Joshi P, Shanker V, Ansari ZA, Singh SP, Chakrabarti P. Contrasting effect of gold nanoparticles and nanorods with different surface modifications on the structure and activity of bovine serum albumin. Langmuir: ACS J Surface Colloids 2011;27:7722-31.
66. Dobrovolskaia MA, Patri AK, Zheng J, Clogston JD, Ayub N, Aggarwal P, et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomed: Nanotechnol, Biol Med 2009;5:106-17.
67. Dutta D, Sundaram SK, Teeguarden JG, Riley BJ, Fifield LS, Jacobs JM, et al. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol Sci: An Off J Soc Toxicol 2007;100:303-15.
68. Lindman S, Lynch I, Thulin E, Nilsson H, Dawson KA, Linse S. Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. Nano Lett 2007;7:914-20.
69. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 2011;63:24-46.
70. Lundqvist M, Stigler J, Cedervall T, Berggrd T, Flanagan MB, Lynch I, et al. The evolution of the protein corona around nanoparticles: a test study. ACS Nano 2011;5:7503-9.
71. Barran-Berdon AL, Pozzi D, Caracciolo G, Capriotti AL, Caruso G, Cavaliere C, et al. Time evolution of nanoparticle-protein corona in human plasma: relevance for targeted drug delivery. Langmuir: The ACS J Surfaces and Colloids 2013;29:6485-94.
72. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 2010;4:3623-32.
73. DellOrco D, Lundqvist M, Oslakovic C, Cedervall T, Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS One 2010;5:e10949.
74. Natte K, Friedrich JF, Wohlrab S, Lutzki J, von Klitzing R, Osterle W, et al. Impact of polymer shell on the formation and time evolution of nanoparticle-protein corona. Colloids Surfaces B, Biointerfaces 2013;104:213-20.
75. Rocker C, Potzl M, Zhang F, Parak WJ, Nienhaus GU. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. Nat Nanotechnol 2009;4:577-80.
76. Ehrenberg MS, Friedman AE, Finkelstein JN, Oberdorster G, McGrath JL. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 2009;30:603-10.
77. Goppert TM, Muller RH. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur J Pharm Biopharm 2005;60:361-72.
78. Labarre D, Vauthier C, Chauvierre C, Petri B, Muller R, Chehimi MM. Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials 2005;26:5075-84.
79. Owens DE, 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307:93-102.
80. Gessner A, Lieske A, Paulke B, Muller R. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm 2002;54:165-70.
81. Mahmoudi M, Abdelmonem AM, Behzadi S, Clement JH, Dutz S, Ejtehadi MR, et al. Temperature: the ignored factor at the NanoBio interface. ACS Nano 2013;7:6555-62.
82. Docter D, Distler U, Storck W, Kuharev J, Wünsch D, Hahlbrock A, et al. Quantitative profiling of the protein coronas that form around nanoparticles. Nat Protocols 2014;9:2030-44.
83. Mahmoudi M, Lohse SE, Murphy CJ, Fathizadeh A, Montazeri A, Suslick KS. Variation of protein corona composition of gold nanoparticles following plasmonic heating. Nano Lett 2014;14:6-12.
84. Caracciolo G, Pozzi D, Capriotti AL, Cavaliere C, Foglia P, Amenitsch H, et al. Evolution of the protein corona of lipid gene vectors as a function of plasma concentration. Langmuir: ACS J Surfaces Colloids 2011;27:15048-53.
85. Zhang H, Pokhrel S, Ji Z, Meng H, Wang X, Lin S, et al. PdO doping tunes band-gap energy levels as well as oxidative stress responses to a Co(3)O(4) p-type semiconductor in cells and the lung. J Am Chem Soc 2014;136:6406-20.
86. Wang X, Ji Z, Chang CH, Zhang H, Wang M, Liao Y-P, et al. Use of coated silver nanoparticles to understand the relationship of particle dissolution and bioavailability to cell and lung toxicological potential. Small 2014;10:385-98.
87. Gilbert B, Fakra SC, Xia T, Pokhrel S, Madler L, Nel AE. The fate of ZnO nanoparticles administered to human bronchial epithelial cells. ACS Nano 2012;6:4921-30.
88. Konduru N, Keller J, Ma-Hock L, Gröters S, Landsiedel R, Donaghey TC, et al. Biokinetics and effects of barium sulfate nanoparticles. Particle and Fibre Toxicology 2014;11:55.
89. Li R, Ji Z, Chang CH, Dunphy DR, Cai X, Meng H, Zhang H, et al. Surface interactions with compartmentalized cellular phosphates explain rare earth oxide nanoparticle hazard and provide opportunities for safer design. ACS Nano 2014;8:1771-83.
90. Anderson JW, Semprini L, Radniecki TS. Influence of water hardness on silver ion and silver nanoparticle fate and toxicity toward. Environ Eng Sci 2014;31:403-9.
91. Kelly PM, Aberg C, Polo E, OConnell A, Cookman J, Fallon J, et al. Mapping protein binding sites on the biomolecular corona of nanoparticles. Nat Nanotechnol 2015;10:472-9.
92. Barkam S, Saraf S, Seal S. Fabricated micro-nano devices for in vivo and in vitro biomedical applications. Wiley Interdisciplin Rev Nanomed Nanobiotechnol 2013;5:544-68.
93. Moghimi SM, Farhangrazi ZS. Nanomedicine and the complement paradigm. Nanomed: Nanotechnol, Biol Med 2013;9:458-60.
94. Lesniak A, Fenaroli F, Monopoli MP, Aberg C, Dawson KA, Salvati A. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. ACS Nano 2012;6:5845-57.
95. Huhn D, Kantner K, Geidel C, Brandholt S, De Cock I, Soenen SJ, et al. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. ACS Nano 2013;7:3253-63.
96. Lesniak A, Salvati A, Santos-Martinez MJ, Radomski MW, Dawson KA, Aberg C. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J Am Chem Soc 2013;135:1438-44.
97. Meister S, Zlatev I, Stab J, Docter D, Baches S, Stauber RH, et al. Nanoparticulate flurbiprofen reduces amyloid-beta42 generation in an in vitro blood-brain barrier model. Alz Res Therapy 2013;5:51.
98. Zhu M, Nie G, Meng H, Xia T, Nel A, Zhao Y. Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Accounts Chem Res 2013;46:622-31.
99. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliver Rev 2009;61:428-37.
100. Dobrovolskaia MA, Germolec DR, Weaver JL. Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol 2009;4:411-4.
101. Sacchetti C, Motamedchaboki K, Magrini A, Palmieri G, Mattei M, Bernardini S, et al. Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance. ACS Nano 2013;7:1974-89.
102. Murthy AK, Stover RJ, Borwankar AU, Nie GD, Gourisankar S, Truskett TM, et al. Equilibrium gold nanoclusters quenched with biodegradable polymers. ACS Nano 2013;7:239-51.
103. Pozzi D, Colapicchioni V, Caracciolo G, Piovesana S, Capriotti AL, Palchetti S, et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale 2014;6:2782-92.
104. Moyano DF, Saha K, Prakash G, Yan B, Kong H, Yazdani M, et al. Fabrication of corona-free nanoparticles with tunable hydrophobicity. ACS Nano 2014;8:6748-55.
105. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013;8:137-43.
106. von Maltzahn G, Park JH, Lin KY, Singh N, Schwöppe C, Mesters R, et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater 2012;10:545-52.
107. Helou M, Reisbeck M, Tedde SF, Richter L, Bär L, Bosch JJ, et al. Time-of-flight magnetic flow cytometry in whole blood with integrated sample preparation. Lab on a chip 2013;13:1035-8.
108. Docter D, Bantz C, Westmeier D, Galla HJ, Wang Q, Kirkpatrick JC, et al. The protein-corona protects against size- and dose-dependent toxicity of amorphous silica nanoparticles. Beilstein J Nanotechnol 2014;5:1380-92.
109. Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 2008;122:452-60.
110. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007;2:469-78.
111. Vroman L. Effect of absorbed proteins on the wettability of hydrophilic and hydrophobic solids. Nature 1962;196:476-7.
112. Vogler EA. Protein adsorption in three dimensions. Biomaterials 2012;33:1201-37.
113. Liu TP, Wu SH, Chen YP, Chou CM, Chen CT. Biosafety evaluations of well-dispersed mesoporous silica nanoparticles: towards in vivo-relevant conditions. Nanoscale 2015;7:6471-80.
114. Shannahan JH, Podila R, Aldossari AA, Emerson H, Powell BA, Ke PC, et al. Formation of a protein corona on silver nanoparticles mediates cellular toxicity via scavenger receptors. Toxicol Sci: An Off J Soc Toxicol 2015;143:136-46.
115. Ge C, Du J, Zhao L, Wang L, Liu Y, Li D, et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity. Proc Natl Acad Sci USA 2011;108:16968-73.
116. Hu W, Peng C, Lv M, Li X, Zhang Y, Chen N, et al. Protein corona- mediated mitigation of cytotoxicity of graphene oxide. ACS Nano 2011;5:3693-700.
117. Sim RB, Wallis R. Surface properties: Immune attack on nanoparticles. Nat Nanotechnol 2011;6:80-1.
118. Hulander M, Lundgren A, Berglin M, Ohrlander M, Lausmaa J, Elwing H. Immune complement activation is attenuated by surface nanotopography. Int J Nanomed 2011;6:2653-66.
119. Bertholon I, Vauthier C, Labarre D. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharmaceut Res 2006;23:1313-23.
120. Nel A, Xia T, Meng H, Wang X, Lin S, Ji Z, et al. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. Accounts Chem Res 2012;46:607-21.
121. Damoiseaux R, George S, Li M, Pokhrel S, Ji Z, France B, et al. No time to lose - high throughput screening to assess nanomaterial safety. Nanoscale 2012;3:1345-60.
122. Roach P, Farrar D, Perry CC. Surface tailoring for controlled protein adsorption: effect of topography at the nanometer scale and chemistry. J Am Chem Soc 2006;128:3939-45.
123. Patel T, Telesca D, Rallo R, George S, Xia T, Nel AE. Hierarchical rank aggregation with applications to nanotoxicology. J Agric Biol Environ Stat 2013;18:159-77.
124. Liu R, Zhang HY, Ji ZX, Rallo R, Xia T, Chang CH, et al. Development of structure-Activity relationship for metal oxide nanoparticles. Nanoscale 2013;5:5644-53.
125. Liu R, Rallo R, Weissleder R, Tassa C, Shaw S, Cohen Y. Nano-SAR development for bioactivity of nanoparticles with considerations of decision boundaries. Small 2013;9:1842-52.
126. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature 2013;501:373-9.
127. Kasper J, Hermanns MI, Bantz C, Maskos M, Stauber R, Pohl C, et al. Inflammatory and cytotoxic responses of an alveolar-capillary coculture model to silica nanoparticles: comparison with conventional monocultures. Particle Fibre Toxicol 2011;8:6.
128. Lehmann AD, Daum N, Bur M, Lehr CM, Gehr P, Rothen- Rutishauser BM. An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. Eur J Pharm Biopharm 2011;77:398-406.
129. Nguyen TA, Yin TI, Reyes D, Urban GA. Microfluidic chip with integrated electrical cell-impedance sensing for monitoring single cancer cell migration in three-dimensional matrixes. Anal Chem 2013;85:11068-76.
130. Nel A, Zhao Y, Madler L. Environmental health and safety considerations for nanotechnology. Accounts Chem Res 2013;46:605-6.
131. Lin S, Zhao Y, Nel AE. Zebrafish: an in vivo model for nano EHS studies. Small 2013;9:1608-18.
132. Gomes SI, Soares AM, Scott-Fordsmand JJ, Amorim MJ. Mechanisms of response to silver nanoparticles on Enchytraeus albidus (Oligochaeta): survival, reproduction and gene expression profile. J Hazard Mater 2013;254-255:336-44.
133. Zhang Y, Bai Y, Jia J, Gao N, Li Y, Zhang R, et al. Perturbation of physiological systems by nanoparticles. Chem Soc Rev 2014;43:3762-809.
134. Fernandez MD, Alonso-Blazquez MN, Garcia-Gomez C, Babin M. Evaluation of zinc oxide nanoparticle toxicity in sludge products applied to agricultural soil using multispecies soil systems. Sci Tot Environm 2014;497-498:688-96.
135. Sakulkhu U, Maurizi L, Mahmoudi M, Motazacker M, Vries M, Gramoun A, et al. Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. Nanoscale 2014;6:11439-50.
136. Lin S, Zhao Y, Ji Z, Ear J, Chang CH, Zhang H, et al. Zebrafish high-throughput screening to study the impact of dissolvable metal oxide nanoparticles on the hatching enzyme, ZHE1. Small 2013;9:1776-85.